← Statins × lipids

TrialCirculation2014

Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

Amit V Khera et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 7,746 people · 2014

Not counted

Lowered lipids

−38%−57% to −10%

Bigger than 7 in 10 on the map

As reported

HR 0.62, 95% CI 0.43–0.90

Not counted

Lowered lipids

−54%−70% to −28%

Bigger than 8 in 10 on the map

As reported

HR 0.46, 95% CI 0.30–0.72

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with higher lipids

+27%+1% to +59%

Bigger than 5 in 10 on the map

As reported

HR 1.27, 95% CI 1.01–1.59

Three numbers in the abstract

the abstract, start to end

… disease (adjusted hazard ratio, 1.27; 95% confidence interval, …

… or equal to the median (hazard ratio, 0.62; 95% confidence interval, 0.43-0.90) and Lp(a) less than the median (hazard ratio, 0.46; 95% confidence interval, …

← favours treatmentfavours comparator →
could be chance
Lipids
HR 1.271.01–1.59
Lipids
HR 0.620.43–0.90
Lipids
HR 0.460.30–0.72
StatinsLipids
1 / 3

179 papers cite itlatest 60 shown

2014
…
2016
2017
2018
2020
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT00239681phase 317,802 enrolled2003
Full record →Abstract, authors, funding and every citing paper · PMID 24243886